APA (7th ed.) Citation

Eyerich, K., Asadullah, K., Pinter, A., Weisenseel, P., Reich, K., Paul, C. F., . . . Schäkel, K. (2024). Noninferiority of 16-week vs 8-week guselkumab dosing in super responders for maintaining control of psoriasis: The GUIDE randomized clinical trial. JAMA dermatology, 160(9), . https://doi.org/10.1001/jamadermatol.2024.2463

Chicago Style (17th ed.) Citation

Eyerich, Kilian, et al. "Noninferiority of 16-week Vs 8-week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial." JAMA Dermatology 160, no. 9 (2024). https://doi.org/10.1001/jamadermatol.2024.2463.

MLA (9th ed.) Citation

Eyerich, Kilian, et al. "Noninferiority of 16-week Vs 8-week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial." JAMA Dermatology, vol. 160, no. 9, 2024, https://doi.org/10.1001/jamadermatol.2024.2463.